HC Wainwright Has Negative Estimate for Humacyte Q3 Earnings

by · The Markets Daily

Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Humacyte in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.09). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.09 EPS and FY2030 earnings at $0.31 EPS.

Several other equities analysts have also commented on the stock. Benchmark dropped their price target on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. TD Cowen decreased their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research report on Wednesday, August 12th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.11.

Get Our Latest Stock Analysis on Humacyte

Humacyte Price Performance

HUMA opened at $0.58 on Monday. Humacyte has a 1 year low of $0.53 and a 1 year high of $2.55. The company’s 50 day simple moving average is $0.74 and its 200 day simple moving average is $0.89. The stock has a market capitalization of $156.85 million, a PE ratio of -1.19 and a beta of 2.54. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Humacyte (NASDAQ:HUMA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%.

Institutional Investors Weigh In On Humacyte

Several institutional investors have recently bought and sold shares of HUMA. R Squared Ltd purchased a new position in shares of Humacyte in the 4th quarter valued at $25,000. Atom Investors LP acquired a new position in shares of Humacyte during the 4th quarter valued at $25,000. Beacon Pointe Advisors LLC purchased a new stake in Humacyte during the 2nd quarter worth $28,000. Prudential Financial Inc. purchased a new stake in Humacyte during the 2nd quarter worth $28,000. Finally, Financial Advisors Network Inc. acquired a new stake in Humacyte in the 2nd quarter valued at $28,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Further Reading